Stocks · Healthcare · Biotechnology
Cytokinetics, Incorporated CYTK
$65.60 -0.03% Close, Oct 2, 2026 · NASDAQ · Market cap $8.16B
Next earnings report: Nov 4, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -993.0% from -638.0% a year earlier.
- The diluted share count rose 10.6% in a year.
- Revenue over the last four quarters was $71.0M, down 17.2% from a year earlier, slowing from 450.6% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
Growth3Very weak
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 17%
- Revenue growth, 3-year CAGRBottom 19%
- Revenue growth accelerationBottom 1%
Quality53Neutral
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 34%
- Gross marginTop 24%
- Operating marginBottom 12%
- Accruals (lower is better)Top 18%
- Interest coverBottom 39%
Value32Weak
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 43%
- Free-cash-flow yieldBottom 44%
- EBITDA / enterprise valueBottom 41%
- Sales / enterprise valueBottom 7%
Momentum49Neutral
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 45%
- 6-month returnBottom 41%
- 1-year return vs S&P 500Top 46%
- Distance from 52-week highTop 40%
- Trend checklist (0–4)Bottom 38%
Revisions54Neutral
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 26%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyTop 20%
- Upside to consensus price targetTop 47%
Stability77Positive
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 14%
- Maximum drawdown, 3 yearsBottom 47%
- Beta vs S&P 500 (lower is better)Top 36%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 450.6% | -17.2% | ↓ |
| Gross margin | -227.0% | 85.0% | ↑ |
| Operating margin | -638.0% | -993.0% | ↓ |
| FCF margin | -513.7% | -818.4% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -17.2% | 450.6% | ↓ | Bottom 17% |
| Gross margin | 85.0% | -227.0% | ↑ | Top 24% |
| Operating margin | -993.0% | -638.0% | ↓ | Bottom 12% |
| Net margin | -1259.9% | -707.2% | ↓ | — |
| Free-cash-flow margin | -818.4% | -513.7% | ↓ | — |
| Return on invested capital | -39.3% | — | Bottom 34% | |
| Revenue growth, 3-year CAGR | -2.4% | — | Bottom 19% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -17.6%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 136.4%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +207.7 pp
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -5.6×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -10.18%
- Shareholder yield
- -10.18%
- Share count change, 1 year
- +10.6%
- Share count change, 3-year CAGR
- +11.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 4 of 8
- Average EPS surprise, last 4
- -13.4%
- Average 2-day reaction, last 8
- +2.7%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $112.50
- Target vs current price
- +71.5%
- Analysts with a rating
- 35
- Share rating Buy or Strong Buy
- 97%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +8.0% | +3.2% | -4.1% | -8.8% | — |
| May 5, 2026 | +0.0% | +16.7% | +12.9% | +7.4% | +21.8% |
| Feb 24, 2026 | -1.4% | +2.7% | -10.0% | -10.7% | +12.0% |
| Nov 5, 2025 | -60.4% | -0.7% | +11.5% | +8.5% | +9.3% |
| Aug 7, 2025 | +16.4% | +0.3% | +5.0% | +41.6% | +77.1% |
| May 6, 2025 | +3.5% | -7.4% | -12.4% | -12.7% | +2.6% |
| Feb 27, 2025 | +2.3% | +1.3% | -6.4% | -6.9% | -34.9% |
| Nov 6, 2024 | -7.1% | +5.7% | +7.0% | -4.0% | -6.3% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$1.50 | -$1.63 | +8.0% | $28.6M |
| May 5, 2026 | -$1.67 | -$1.67 | +0.0% | $19.4M |
| Feb 24, 2026 | -$1.50 | -$1.48 | -1.4% | $17.8M |
| Nov 5, 2025 | -$2.55 | -$1.59 | -60.4% | $1.9M |
| Aug 7, 2025 | -$1.12 | -$1.34 | +16.4% | $66.8M |
| May 6, 2025 | -$1.36 | -$1.41 | +3.5% | $1.6M |
| Feb 27, 2025 | -$1.26 | -$1.29 | +2.3% | $16.9M |
| Nov 6, 2024 | -$1.36 | -$1.27 | -7.1% | $463,000 |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 129.34× | — | — | Bottom 7% |
| Free-cash-flow yield | -7.11% | — | — | Bottom 44% |
| Earnings yield | -11.01% | — | — | Bottom 43% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -7.2%
- 200-day average slope (20 days)
- +0.6%
- Distance from 50-day average
- -10.9%
- Distance from 200-day average
- -6.5%
- RSI (14)
- 33.4
- Relative volume
- 1.29×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 33.8%
- Volatility vs own 5-year history
- 1th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.89
- Correlation with S&P 500
- 0.24
- Current drawdown from 1-year high
- -24.8%
- Maximum drawdown, 3 years
- -72.4%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jan 8, 2024 | May 15, 2025 | -72.4% | 339 days | Not yet recovered |
| Sep 9, 2022 | Oct 3, 2023 | -50.7% | 267 days | 59 days (Dec 27, 2023) |
| Oct 5, 2020 | Oct 9, 2020 | -46.7% | 4 days | 194 days (Jul 20, 2021) |
| Dec 29, 2021 | Jan 27, 2022 | -35.9% | 20 days | 101 days (Jun 23, 2022) |
| Jun 27, 2022 | Jul 18, 2022 | -21.2% | 14 days | 14 days (Aug 5, 2022) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $8.16B
- EPS, diluted (TTM)
- -$7.22
- Revenue (TTM)
- $71.0M
- 52-week range
- $54.30 – $88.31
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $70.4M | $94.6M | $7.5M | $18.5M | $88.0M |
| Gross profit | -$89.5M | -$146.2M | -$322.6M | -$320.9M | $77.9M |
| Operating income | -$186.3M | -$324.2M | -$496.2M | -$536.2M | -$612.3M |
| Net income | -$215.3M | -$389.0M | -$526.2M | -$589.5M | -$785.0M |
| EPS (diluted) | -$2.80 | -$4.33 | -$5.45 | -$5.26 | -$6.54 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $463,000 | $16.9M | $1.6M | $66.8M | $1.9M | $17.8M | $19.4M | $31.9M |
| Net income | -$160.5M | -$150.0M | -$161.4M | -$134.4M | -$306.2M | -$183.0M | -$206.0M | -$198.8M |
| EPS (diluted) | -$1.36 | -$1.27 | -$1.36 | -$1.12 | -$2.55 | -$1.50 | -$1.67 | -$1.50 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$142.5M | -$299.5M | -$414.3M | -$395.9M | -$510.0M |
| Capital expenditure | -$48.9M | -$11.3M | -$1.4M | -$3.9M | -$24.8M |
| Free cash flow | -$191.4M | -$310.9M | -$415.7M | -$399.8M | -$534.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $312.0M | $17.5M | $164.2M | $706.8M | $36.0M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $1.17B
- Total assets
- $1.92B
- Total liabilities
- $2.10B
- Total debt
- $1.27B
- Net debt
- $1.02B
- Shareholders’ equity
- -$173.5M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 17,481,383
- Days to cover
- 10.55
- Change vs previous report
- +0.2%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jun 25, 2013
- 1-for-6